小儿支气管哮喘急性发作的药物治疗进展

Advances in Drug Therapy for Acute Attack of Bronchial Asthma in Children

目前临床上较常见的儿科疾病是小儿支气管哮喘,主要是指多项细胞或细胞组分参与的气道慢性炎症性疾病,往往与气道高反应性有直接联系,主要受到可逆性气流的限制,患儿往往表现为胸闷气短、反复性喘息与咳嗽等临床症状,在晨间或夜间易发作,若疾病早期不能实施有效的治疗措施,则极易对患儿的生活质量造成直接影响,病情严重者可危及生命,因此以患儿病情为基点,切实采取有效的治疗手段对改善其预后效果具有极重要的意义。本文分析小儿支气管哮喘急性发作的药物治疗进展,以供参考。

At present, the most common clinical pediatric disease was bronchial asthma in children, which mainly refers to chronic inflammatory airway diseases involving many cells or cell components. It was often directly related to airway hyperresponsiveness and was mainly restricted by reversible airflow. Children often show clinical symptoms such as shortness of breath, recurrent wheezing and cough. They were prone to attack in the morning or at night. Failure to implement effective treatment measures in the early stage of the disease will easily have a direct impact on the quality of life of the children. Those who were seriously ill may endanger their lives. Therefore, it is of great significance to take effective treatment measures to improve the prognosis of the children based on their condition. This article analyzed the progress of drug treatment for acute attack of bronchial asthma in children for reference.